Advances in the clinical development of oncolytic viruses
10.3781/j.issn.1000-7431.2024.2311-0609
- VernacularTitle:溶瘤病毒疗法的临床研究进展
- Author:
Min YU
1
;
Jie XU
;
Miao ZHU
;
Fei WANG
;
Qiongni LIU
;
Li YANG
;
Tian ZHOU
;
Shaohua YAN
Author Information
1. 北京中医药大学第二临床医学院,北京 100029
- Publication Type:Journal Article
- Keywords:
Oncolytic virus;
Immunotherapy;
Clinical trial
- From:
Tumor
2024;44(10):1033-1043
- CountryChina
- Language:Chinese
-
Abstract:
Oncolytic virus is a unique anti-tumor immunotherapy that can specifically infect and lyse tumor cells,while inducing and activating the body's own anti-tumor immune response to attack tumors.So far,three oncolytic viruses have been approved for marketing.In 2005,China first approved recombinant human adenovirus type 5(H101/Oncorine)combined with chemotherapy for the treatment of advanced nasopharyngeal cancer patients.In 2015,the US Food and Drug Administration(FDA)approved herpes simplex virus type I(T-VEC)for the treatment of recurrent melanoma after primary surgery,T-VEC was subsequently approved in Europe.In 2021,Japan's Ministry of Health,Labour and Welfare approved third-generation recombinant herpes simplex virus type I(Delytact/G47Δ)for the treatment of malignant glioma.Although the approval of H101 in China marks a breakthrough in the development of oncolytic viruses,compared to T-VEC and Delytact,H101 has not significantly impacted the treatment of patients with advanced nasopharyngeal carcinoma.This may be due to its inability to provide a complete tumor response as a monotherapy,and the fact that most nasopharyngeal carcinoma patients in China undergo radiotherapy,making it difficult for them to benefit from chemotherapy combined with H101.Therefore,this treatment regimen still needs improvement.In recent years,with the maturity of genetic engineering technology,oncolytic viruses have been continuously improved and refined.This review summarizes the clinical research progress of oncolytic viruses and discusses their characteristics and development prospects.
